Androgen Receptor Signalling in Prostate Cancer : The Functional Consequences of Acetylation

The androgen receptor (AR) is a ligand activated transcription factor and member of the steroid hormone receptor (SHR) subfamily of nuclear receptors. In the early stages of prostate carcinogenesis, tumour growth is dependent on androgens, and AR directly mediates these effects by modulating gene ex...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2011-01, Vol.2011 (2011), p.1-7
Main Authors: Lavery, Derek N., Bevan, Charlotte L.
Format: Article
Language:English
Subjects:
Acetylation
Androgens
Animals
Care and treatment
Development and progression
Gene expression
Genetic aspects
Histone Acetyltransferases - metabolism
Histone Deacetylases - metabolism
Humans
Male
Medical research
Physiological aspects
Prostate cancer
Prostatic Neoplasms - enzymology
Prostatic Neoplasms - metabolism
Proteins
Receptors, Androgen - metabolism
Review
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The androgen receptor (AR) is a ligand activated transcription factor and member of the steroid hormone receptor (SHR) subfamily of nuclear receptors. In the early stages of prostate carcinogenesis, tumour growth is dependent on androgens, and AR directly mediates these effects by modulating gene expression. During transcriptional regulation, the AR recruits numerous cofactors with acetylation-modifying enzymatic activity, the best studied include p300/CBP and the p160/SRC family of coactivators. It is known that recruitment of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is key in fine-tuning responses to androgens and is thus likely to play a role in prostate cancer progression. Further, these proteins can also modify the AR itself. The functional consequences of AR acetylation, the role of modifying enzymes in relation to AR transcriptional response, and prostate cancer will be discussed.
ISSN:1110-7243
2314-6133
1110-7251
2314-6141
DOI:10.1155/2011/862125